MedTrace Logo

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

NCT01683084 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2020-05-26

No results posted yet for this study

Summary

The purpose of this study is to determine if telmisartan is effective in slowing the progression of abdominal aortic aneurysms and reducing circulating concentrations of Abdominal Aortic Aneurysms (AAA) biomarkers.

Conditions

  • Abdominal Aortic Aneurysm

Interventions

DRUG

Telmisartan

DRUG

Placebo

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • James Cook University, Queensland, Australia

    collaborator OTHER

  • Palo Alto Veterans Institute for Research

    lead OTHER

Principal Investigators

  • Ronald L Dalman, M.D. · PAIRE: Stanford University, VA Palo Alto Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-19
Primary Completion
2018-11-10
Completion
2018-11-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01683084 on ClinicalTrials.gov